Opendata, web and dolomites

Delirium Monitor

Objective delirium detection with an innovative EEG-based spot monitor

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Delirium Monitor project word cloud

Explore the words cloud of the Delirium Monitor project. It provides you a very rough idea of what is the project "Delirium Monitor" about.

rate    noise    sometimes    brain    frightening    nl    2017    134    hospital    impairs    granted    months    create    80    stresses    millions    sme    serious    dementia    customers    automated    times    surgical    yearly    ce    generates    biomarker    validation    functioning    aging    world    device    frequency    detect    detection    prolonged    monitored    certification    risk    patch    billion    icu    hospitalized    recording    mount    undertreated    market    40    patent    start    fatal    unmet    double    utrecht    million    burden    electrode    commercialize    horrifying    elderly    total    clinical    despite    healthcare    specialized    commit    care    disposable    budget    equaling    hallucinations    incidences    stay    sales    mm    showed    patients    medical    impaired    day    decline    costly    usa    nursing    delirium    eeg    minute    thereafter    reported    employees    outcome    length    70    2021    society    revenue    feasibility    electrodes    cognitive    2016    decades    grows    engineering    license    first    alone    diabetes    underdiagnosed    intensive    home    umc    discharge    acute   

Project "Delirium Monitor" data sheet

The following table provides information about the project.

Coordinator
WILLEMS-TJOE NIJ ANNEMARIE CHRISTINE 

Organization address
address: FRED PETTERBAAN 21
city: AMSTERDAM
postcode: 1019 JT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.prolira.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WILLEMS-TJOE NIJ ANNEMARIE CHRISTINE NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

Delirium –an acute decline in cognitive functioning– is common, serious, frightening, costly and sometimes fatal. Delirium is a great burden for patients because of horrifying hallucinations and impaired outcome and increased risk on dementia. Delirium stresses society because of increased healthcare costs. This is due to prolonged length of hospital stay, and increased rate of discharge to a nursing home thereafter. Costs due to delirium total to €134 billion/year in Europe alone, equaling costs associated with diabetes. Delirium particularly affects hospitalized elderly with reported incidences of 50-80% on the Intensive Care Unit (ICU), and 10-40% in surgical patients. Because of our aging society, patients at risk for delirium will double in the next decades. Despite its frequency and impact, delirium remains underdiagnosed and therefore undertreated. Delirium is not recognized in 50 - 70% of the cases, which impairs outcome. Early and objective detection of delirium is an unmet clinical need. Mount Medical (MM), an SME specialized in medical devices, will create and commercialize the world’s first biomarker based device to detect delirium. UMC Utrecht (NL) showed that 1 minute recording of brain activity (EEG) with only 3 electrodes and automated processing could very well identify patients with delirium. A license on the patent will be granted to MM. Yearly, millions of patients are at risk of delirium that need to be monitored 3 times per day. This generates a €1.4 billion market in the EU and the USA, as for every measurement, a disposable electrode patch is necessary. A 6 months Phase 1 budget enables biomarker validation and development of noise reduction technology to show technical feasibility, and to commit customers into an Early Access program for market feasibility. Phase 2 is for product engineering and CE certification. EU sales start in 2016, and USA sales in 2017. MM grows to €10 million in revenue and 50 employees in 2021.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DELIRIUM MONITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DELIRIUM MONITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More